AbbVie Inc — China drug registrations and re-registration deadlines
9 certificates in the NMPA overseas-manufactured drug database (境外生产药品库), snapshot 2026-06-28. Earliest re-registration deadline: 2027-12-06.
| Approval number | Product | Certificate expires | Re-registration deadline (Art. 82) |
|---|---|---|---|
| 国药准字HJ20130773 | Kaletra 洛匹那韦/利托那韦口服溶液 | 2028-06-06 | 2027-12-06 |
| 国药准字HJ20160425 | Brimonidine Tartrate Eye Drops 酒石酸溴莫尼定滴眼液 | 2029-10-28 | 2029-04-28 |
| 国药准字HJ20160426 | Brimonidine Tartrate Eye Drops 酒石酸溴莫尼定滴眼液 | 2029-10-28 | 2029-04-28 |
| 国药准字SJ20250008 | SKYRIZI 利生奇珠单抗注射液（皮下注射） | 2030-03-03 | 2029-09-03 |
| 国药准字SJ20250009 | Risankizumab Injection 利生奇珠单抗注射液 | 2030-03-03 | 2029-09-03 |
| 国药准字HJ20200053 | VENCLEXTA 维奈克拉片 | 2030-05-22 | 2029-11-22 |
| 国药准字HJ20200054 | VENCLEXTA 维奈克拉片 | 2030-05-22 | 2029-11-22 |
| 国药准字HJ20200055 | VENCLEXTA 维奈克拉片 | 2030-05-22 | 2029-11-22 |
| 国药准字SJ20260002 | SKYRIZI 利生奇珠单抗注射液（皮下注射） | 2031-01-13 | 2030-07-13 |
Under the Provisions for Drug Registration (药品注册管理办法) Art. 82, an application to renew an overseas-manufactured drug registration is filed with the Center for Drug Evaluation no later than 6 months before the certificate expires; the filing line column is that arithmetic applied to the expiry cell. Art. 84(1): a certificate with no application by expiry is not re-registered and is cancelled at expiry. Every figure is taken from the public NMPA database as of 2026-06-28, or computed from it. Registration data changes; the NMPA portal governs. This page states no view on whether any of these products' Domestic Responsible Person (境内责任人) arrangements meet NMPA Announcement No. 137 — that cannot be determined from a public entry.